PMID- 33930896
OWN - NLM
STAT- MEDLINE
DCOM- 20220429
LR  - 20221207
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 130
IP  - 4
DP  - 2022 Apr
TI  - Increased Serum WISP1 Levels are Associated with Lower Extremity Atherosclerotic 
      Disease in Patients with Type 2 Diabetes Mellitus.
PG  - 248-253
LID - 10.1055/a-1474-8220 [doi]
AB  - BACKGROUND: Serum wnt1-induced signaling pathway protein 1 (WISP1) levels are 
      increased with obesity, which is a common complication associated with lower 
      extremity atherosclerotic disease (LEAD). However, to date, the relationship 
      between elevated WISP1 levels and the incidence of lower extremity 
      atherosclerotic disease (LEAD) in type 2 diabetes mellitus (T2DM) remains 
      unclear. METHODS: 174 newly diagnosed type 2 diabetic patients were enrolled in 
      our study. Patients were divided into two groups, LEAD group (n=100) and control 
      group (n=74). Anthropometric parameters, blood pressure and some biochemical 
      parameters were obtained. Body composition was detected by bioelectrical 
      impedance analysis (BIA). Levels of serum insulin were determined by 
      radioimmunoassay. Serum WISP1 and interleukin 6 (IL-6) levels were determined 
      using an enzyme-linked immunosorbent assay. RESULTS: It was shown that serum 
      WISP1 levels in diabetic patients with LEAD were higher than those without LEAD 
      (P<0.001). Serum WISP1 levels were positively related with waist circumference 
      (r=0.237, P=0.003), waist-hip ratio (r=0.22, P=0.006), visceral fat area 
      (r=0.354, P<0.001), serum creatinine (r=0.192, P=0.012), interleukin 6 (r=0.182, 
      P=0.032), c-reactive protein (r=0.681, P<0.001), triglycerides (r=0.119, 
      P<0.001), fasting glucose (r=0.196, P=0.011), glycated hemoglobin (r=0.284, 
      P<0.001), and HOMA-IR (r=0.285, P<0.026). Compared with the lowest tertile, the 
      odds ratio of the middle tertile for LEAD incidence was 3.27 (95% CI, 1.24-8.64) 
      and 4.46 (95% CI, 1.62-12.29) for the highest tertile after adjusting confounding 
      factors. CONCLUSION: The results suggest that increased serum WISP1 levels 
      independently contribute to the incidence of LEAD in patients with newly 
      diagnosed T2DM.
CI  - Thieme. All rights reserved.
FAU - Cheng, Yangyang
AU  - Cheng Y
AD  - Department of Endocrinology, Central Theater Command General Hospital of the 
      Chinese People's Liberation Army, Wuhan, 430070, Hubei, China.
FAU - Du, Xiaohui
AU  - Du X
AD  - Department of Endocrinology, Central Theater Command General Hospital of the 
      Chinese People's Liberation Army, Wuhan, 430070, Hubei, China.
FAU - Zhang, Bilin
AU  - Zhang B
AD  - Department of Endocrinology, Central Theater Command General Hospital of the 
      Chinese People's Liberation Army, Wuhan, 430070, Hubei, China.
FAU - Zhang, Junxia
AU  - Zhang J
AD  - Department of Endocrinology, Central Theater Command General Hospital of the 
      Chinese People's Liberation Army, Wuhan, 430070, Hubei, China.
LA  - eng
GR  - Bethune-Merck Diabetes Research Foundation/NO. G2018030/
GR  - China Diabetes Young Scientific Talent Research Project/Number 2020-N-01/
PT  - Journal Article
DEP - 20210430
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German 
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
RN  - 0 (CCN Intercellular Signaling Proteins)
RN  - 0 (CCN4 protein, human)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Interleukin-6)
RN  - 0 (Proto-Oncogene Proteins)
SB  - IM
MH  - *Atherosclerosis/epidemiology/etiology
MH  - Body Mass Index
MH  - CCN Intercellular Signaling Proteins
MH  - *Diabetes Mellitus, Type 2
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - *Insulin Resistance
MH  - Interleukin-6
MH  - Lower Extremity
MH  - Proto-Oncogene Proteins
MH  - Signal Transduction
COIS- All authors declare no conflict of interest and grant to submission.
EDAT- 2021/05/01 06:00
MHDA- 2022/04/30 06:00
CRDT- 2021/04/30 20:38
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2022/04/30 06:00 [medline]
PHST- 2021/04/30 20:38 [entrez]
AID - 10.1055/a-1474-8220 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2022 Apr;130(4):248-253. doi: 10.1055/a-1474-8220. 
      Epub 2021 Apr 30.